Celltrion’s Truxima approved in Australia

(Ref: The Korea Herald)

Australia's Therapeutic Goods Administration has approved Celltrion's biosimilar Truxima, The Korea Herald reported Friday.
The therapy is a biosimilar of Roche's MabThera.
Additionally, the drug is Celltrion's second biosimilar to gain clearance in the country after Remsima.
FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>